Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone
Key takeaways
- Ken Langone projects Eli Lilly could reach $2,000 per share in 3–4 years, a 70.92% upside from today’s price, driven by a strong pipeline and Medicare gains.
- $2,000 target is 70.92% above Tuesday’s close
- $1,170.14 closing price
- 55% YTD gain
What happened
Home Depot co‑founder Ken Langone told CNBC that Eli Lilly (LLY) could hit a $2,000 share price in three to four years, a target 70.92% above Tuesday’s close. Langone said Lilly is his largest personal holding and that the drugmaker is outpacing Home Depot in his portfolio. He cited Lilly’s leadership, research spend and pipeline breadth as the basis for the upside.
Why it matters
The forecast signals a significant upside for LLY, potentially reshaping its valuation and investor perception. It highlights Lilly’s expanding pipeline beyond GLP‑1 drugs and its recent Medicare market capture, suggesting sustained growth. The comparison to Home Depot underscores the magnitude of the upside and may…
Short-term and longer-term
Short-term. Short‑term traders should watch LLY’s price action around the $1,170 level, as the $2,000 target implies a 70% upside.
Longer-term. Long‑term investors see Lilly’s diversified pipeline and Medicare penetration as a foundation for sustained growth.